Role of Cilostazol Therapy in Hemodialysis Patients with Asymptomatic Peripheral Arterial Disease: A Retrospective Cohort Study

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Lim, Paik Seong ^a,b,c   Jeng, Yachung ^a,c   Wu, Ming Ying ^a   Pai, Mei Ann ^a   Wu, Tsai Kun ^a   Chen, Chang Hsu ^a  

^a TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c Jenteh Junior College of Medicine Nursing and Manegement No79 9   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; ANTITHROMBOCYTIC AGENT; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RETROSPECTIVE STUDY; RISK; AGED; ANKLE BRACHIAL INDEX; COMPLICATION; KAPLAN MEIER METHOD; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; STROKE;

AGED; ANKLE BRACHIAL INDEX; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK; STROKE; TETRAZOLES;

EID: 84990922593     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/8236903     Document Type: Article

References (39)

1. S. Rajagopalan, S. Dellegrottaglie, A. L. Furniss et al., "Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS), " Circulation, vol. 114, no. 18, pp. 1914-1922, 2006.
2. A. Guerrero, R. Montes, J. Muñoz-Terol et al., "Peripheral arterial disease in patients with stages IV and V chronic renal failure, " Nephrology Dialysis Transplantation, vol. 21, no. 12, pp. 3525-3531, 2006.
3. A. M. O'Hare, C.-Y. Hsu, P. Bacchetti, and K. L. Johansen, "Peripheral vascular disease risk factors among patients undergoing hemodialysis, " Journal of theAmerican Society of Nephrology, vol. 13, no. 2, pp. 497-503, 2002.
4. S. G. De Vinuesa, M. Ortega, P. Martinez, M. Goicoechea, F. G. Campdera, and J. Luño, "Subclinical peripheral arterial disease in patients with chronic kidney disease: prevalence and related risk factors, " Kidney International, vol. 67, supplement 93, pp. S44-S47, 2005.
5. S. Fishbane, S. Youn, E. Flaster, G. Adam, and J. K. Maesaka, "Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients, " American Journal of Kidney Diseases, vol. 27, no. 5, pp. 668-672, 1996.
6. K. Ono, A. Tsuchida, H. Kawai et al., "Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients, " Journal of the American Society of Nephrology, vol. 14, no. 6, pp. 1591-1598, 2003.
7. T. Kitahara, K. Ono, A. Tsuchida et al., "Impact of brachial-ankle pulse wave velocity and ankle-brachial blood pressure index on mortality in hemodialysis patients, "American Journal of Kidney Diseases, vol. 46, no. 4, pp. 688-696, 2005.
8. Y. Luo, X. Li, J. Li et al., "Peripheral arterial disease, chronic kidney disease, and mortality: The Chinese Ankle Brachial Index Cohort Study, " Vascular Medicine, vol. 15, no. 2, pp. 107-112, 2010.
9. A. O'Hare and K. Johansen, "Lower-extremity peripheral arterial disease among patients with end-stage renal disease, " Journal of theAmerican Society of Nephrology, vol. 12, no. 12, pp. 2838-2847, 2001.
10. P. Alonso-Coello, S. Bellmunt, C. McGorrian et al., "Antithrombotic therapy in peripheral artery disease-antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines, " Chest, vol. 141, no. 2, supplement, pp. e669S-e690S, 2012.
11. T. W. Rooke, A. T. Hirsch, S. Misra et al., "2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, " Journal of the American College of Cardiology, vol. 58, no. 19, pp. 2020-2045, 2011.
12. C. Baigent, C. Sudlow, R. Collins, and R. Peto, "Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, " British Medical Journal, vol. 324, no. 7329, pp. 71-86, 2002.
13. S. C. Palmer, L. DiMicco, M. Razavian et al., "Antiplatelet agents for chronic kidney disease, " Cochrane Database of Systematic Reviews, vol. 2, Article IDCD008834, 2013.
14. N. Jain, S. S. Hedayati, R. Sarode, S. Banerjee, and R. F. Reilly, "Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?" Clinical Journal of the American Society of Nephrology, vol. 8, no. 4, pp. 665-674, 2013.
15. D. E. Strandness Jr., R. L. Dalman, S. Panian et al., "Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study, " Vascular and Endovascular Surgery, vol. 36, no. 2, pp. 83-91, 2002.
16. Y. Huang, Y. Cheng, J. Wu et al., "Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study, " The Lancet Neurology, vol. 7, no. 6, pp. 494-499, 2008.
17. Y. Shinohara, Y. Katayama, S. Uchiyama et al., "Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial, " The Lancet Neurology, vol. 9, no. 10, pp. 959-968, 2010.
18. A. K. Kamal, I. Naqvi, M. R. Husain, and B. A. Khealani, "Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin, " Cochrane Database of Systematic Reviews, no. 1, Article ID CD008076, 2011.
19. S. Uchiyama, B. M. Demaerschalk, S. Goto et al., "Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials, " Journal of Stroke and Cerebrovascular Diseases, vol. 18, no. 6, pp. 482-490, 2009.
20. L.-G. Shi, J.-L. Pu, L. Xu, J. Malaguit, J. Zhang, and S. Chen, "The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population-an updated meta-analysis, " BMC Neurology, vol. 14, no. 1, article 251, 2014.
21. Y. Qian and Q. Bi, "Systematic study of cilostazol on secondary stroke prevention: ameta-analysis, " European Journal ofMedical Research, vol. 18, article 53, 2013.
22. C. J. Estol, P. M. Bath, P. B. Gorelick, D. Cotton, R. H. Martin, and PRoFESS Publications Committee and PRoFESS Investigators, "Differences in ischemic and hemorrhagic recurrence rates among race-ethnic groups in the PRoFESS secondary stroke prevention trial, " International Journal of Stroke, vol. 9, supplement A100, pp. 43-47, 2014.
23. Y. Liu, Y. Shakur, M. Yoshitake, and J.-I. Kambayashi, "Cilostazol (Pletal-): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake, " Cardiovascular Drug Reviews, vol. 19, no. 4, pp. 369-386, 2001.
24. M. Matsumoto, "Cilostazol in secondary prevention of stroke: impact of the cilostazol stroke prevention study, " Atherosclerosis Supplements, vol. 6, no. 4, pp. 33-40, 2005.
25. L. Tan, B. Margaret, J. H. Zhang et al., "Efficacy and safety of cilostazol therapy in ischemic stroke: a meta-analysis, " Journal of Stroke and Cerebrovascular Diseases, vol. 24, no. 5, pp. 930-938, 2015.
26. J. J. Dinicolantonio, C. J. Lavie, H. Fares et al., "Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke, " American Journal of Cardiology, vol. 112, no. 8, pp. 1230-1234, 2013.
27. J. Kambayashi, Y. Liu, B. Sun, Y. Shakur, M. Yoshitake, and F. Czerwiec, "Cilostazol as a unique antithrombotic agent, " Current Pharmaceutical Design, vol. 9, no. 28, pp. 2289-2302, 2003.
28. K. Suzuki, K. Uchida, N. Nakanishi, and Y. Hattori, "Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes, " American Journal of Hypertension, vol. 21, no. 4, pp. 451-457, 2008.
29. C. J. Warner, S. W. Greaves, R. J. Larson et al., "Cilostazol is associated with improved outcomes after peripheral endovascular interventions, " Journal of Vascular Surgery, vol. 59, no. 6, pp. 1607-1614, 2014.
30. Y. Chen, Y. Zhang, Y. Tang, X. Huang, and Y. Xie, "Longterm clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a metaanalysis of randomized trials with adjusted indirect comparisons, " Current Medical Research and Opinion, vol. 30, no. 1, pp. 37-49, 2014.
31. H. Takagi and T. Umemoto, "Benefit, rather than safety, of cilostazol for long-termmortality in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized trials, " International Journal of Cardiology, vol. 153, no. 1, pp. 74-119, 2011.
32. G. Di Minno, A. Cerbone, M. Usberti et al., "Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen, " Journal of Laboratory and Clinical Medicine, vol. 108, no. 3, pp. 246-252, 1986.
33. J. W. Lohr and S. J. Schwab, "Minimizing hemorrhagic complications in dialysis patients, " Journal of the American Society of Nephrology, vol. 2, no. 5, pp. 961-975, 1991.
34. J. Éthier, J. L. Bragg-Gresham, L. Piera et al., "Aspirin prescription and outcomes in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS), " American Journal of Kidney Diseases, vol. 50, no. 4, pp. 602-611, 2007.
35. S. Hiremath, R. M. Holden, D. Fergusson, and D. L. Zimmerman, "Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates, " Clinical Journal of the American Society of Nephrology, vol. 4, no. 8, pp. 1347-1355, 2009.
36. C. Baigent, M. Landray, C. Leaper et al., "First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease, " American Journal of KidneyDiseases, vol. 45, no. 3, pp. 473-484, 2005.
37. S. C. Palmer, L. D. Micco, M. Razavian et al., "Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review andmeta-analysis, " Annals of InternalMedicine, vol. 156, no. 6, pp. 445-459, 2012.
38. M. Kuwahara, S. Hasumi, S. Mandai et al., "Rate of anklebrachial index decline predicts cardiovascular mortality in hemodialysis patients, " Therapeutic Apheresis and Dialysis, vol. 18, no. 1, pp. 9-18, 2014.
39. H. Ogata, C. Kumata-Maeta, K. Shishido et al., "Detection of peripheral artery disease by duplex ultrasonography among hemodialysis patients, " Clinical Journal of the American Society of Nephrology, vol. 5, no. 12, pp. 2199-2206, 2010.